AMGN
$347.80-2.12 (-0.61%)
Amgen Inc.
Recent News
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug declines.
AMGN Trading Above 50 & 200-Day SMA: How to Play the Stock?
Amgen stock holds above key SMAs as strong drug sales, biosimilars, and MariTide pipeline momentum offset looming patent losses and pricing headwinds.
Crossbow raises $77M for new cancer immunotherapies
Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
Amgen Inc. and GSK plc are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs. This move will augment the total number of discounted prescription medications available on the platform to 54, from five different pharmaceutical companies, according to a report by FOX Business on Friday. Amgen will offer an 80% discount on Amjevita, a medication used for rheumatoid arthritis, psoriasis, and ulcerative colitis
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Amgen (AMGN) closed at $361.13 in the latest trading session, marking a -1.4% move from the prior day.